Transdermal Buprenorphine Patch for Post-Surgical Pain in Facial Fractures: A Randomized Controlled Trial

Evaluation of effectiveness of transdermal buprenorphine patch for postoperative pain management in mid face fractures: A randomised clinical trial. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/107358

Enrollment

Registered

2026-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S024- Fracture of malar, maxillary and zygoma bones

Interventions

Intervention1: Buprenorphine patch: Application of Buprenorphine patch post operative patients of mid face fractures for 3 post operative days. Control Intervention1: Intra muscular Diclofenac 75 mg:

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient undergoing elective ORIF for mid-face fractures. 2.Consent to participate

Exclusion criteria

Exclusion criteria: 1.Known allergy to study drugs 2.Chronic opioid usage 3. Hepatic or renal impairment 4. Pregnancy or lactation 5. Active psychiatric illness

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of the transdermal buprenorphine patch (10 g/h) with intramuscular diclofenac (75 mg) in controlling postoperative pain following ORIF of mid-face fractures.Timepoint: Post operatively on 1st, 2nd and 3rd day	—

Secondary

Measure	Time frame
NILTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Abhilasha Lad

Dr DY Patil Dental College and Hospital, Dr DY Patil Vidyapeeth, Pimpri, Pune 411018.

Sonal.shah@dou.edu.in9833459822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026